Get updates on Therapeutic and Biomedical Applications of CRISPRs, ZFNs, TALENs and other Genome Engineering Technologies
Genome Editing Applications
2-3 December 2015
Sheraton Airport Hotel
Brussels, Belgium
Biomedical researchers have long strived for a reliable and efficient method of making targeted changes to the genome of living cells. With the advent of CRISPR/Cas9 researchers are now able to explore gene function in a much more thorough and cost-effective way.
This year, Lorenz Mayer from Astrazenca will be giving a presentation on their genome wide target discovery and target validation studies. Ines Royaux from Janssen Phamaceutica will also be giving a presentation touching on the team’s first experience of using genome editing for ex vivo gene therapy. Read on to find out more about what you can expect to learn from the speakers at this year's conference.
This inaugural event in Europe follows the enormous success of Genome Editing Applications in March 2015 in the US from our sister company, IBC Life Sciences.
*Genome Editing Applications is co-located with Cell Therapy Manufacturing and Gene Therapy conferences with a shared exhibition area
So far, across the three conferences, over 120 have confirmed to attend with representation from biopharm, pharma and biotech companies - including Novartis Pharma AG, Glaxosmithkline, CRISPR Therapeutics, Astrazeneca, F Hoffmann-La Roche AG, GSK Pharma, Hitachi LTD, Bluebird BIO, Sanofi Pasteur, Janssen Pharmaceutica NV, Merck & CO., INC., Precision Biosciences, INC.
Hear from influential industry experts such as:
Genome Editing Applications
2-3 December 2015
Sheraton Airport Hotel
Brussels, Belgium
Biomedical researchers have long strived for a reliable and efficient method of making targeted changes to the genome of living cells. With the advent of CRISPR/Cas9 researchers are now able to explore gene function in a much more thorough and cost-effective way.
This year, Lorenz Mayer from Astrazenca will be giving a presentation on their genome wide target discovery and target validation studies. Ines Royaux from Janssen Phamaceutica will also be giving a presentation touching on the team’s first experience of using genome editing for ex vivo gene therapy. Read on to find out more about what you can expect to learn from the speakers at this year's conference.
Get a sneak peek into the new developments and data the speakers will be sharing during their presentations here.
Informa's Genome Editing Applications 2015 conference, taking place on 2-3 December 2015 in Brussels, will showcase the most up-to-date therapeutic and biomedical applications emerging using CRISPRs, ZFNs, TALENs, AAVs and other genome engineering technologies. From improving lead discovery, validation of targeted cell lines and development of transgenic animal models to therapeutic uses in cell therapy & gene therapy.This inaugural event in Europe follows the enormous success of Genome Editing Applications in March 2015 in the US from our sister company, IBC Life Sciences.
*Genome Editing Applications is co-located with Cell Therapy Manufacturing and Gene Therapy conferences with a shared exhibition area
So far, across the three conferences, over 120 have confirmed to attend with representation from biopharm, pharma and biotech companies - including Novartis Pharma AG, Glaxosmithkline, CRISPR Therapeutics, Astrazeneca, F Hoffmann-La Roche AG, GSK Pharma, Hitachi LTD, Bluebird BIO, Sanofi Pasteur, Janssen Pharmaceutica NV, Merck & CO., INC., Precision Biosciences, INC.
Hear from influential industry experts such as:
REGISTER FOR AS LITTLE AS £799* TODAY
*Based on standard industry rate Biopharm/Pharma/Biotech 2 day conference pass for one attendee. Not including suppliers/vendors.
|
Share this article with your social network, just click below to share now!
|
|
|
No comments :
Post a Comment